Five-Year Survival Rates
(from the National Cancer Institute's Physician Data Query system, July 2003)
Oropharynx
Sub Site |
Stage I |
Stage II |
Stage III |
Stage IV |
All Cases |
Posterior tongue |
60% |
50% |
20% |
20% |
50% |
Tonsil |
70% |
50% |
30% |
14% |
50% |
Posterior pharynx |
77-100%1 |
58-80%1 |
70-75%1 |
41-50%1 |
50% |
Soft palate |
90-100%1 |
80-100%1 |
28-82%1 |
25-83%1 |
50% |
Nasopharynx
Sub Site |
Stage I |
Stage II |
Stage III |
Stage IV |
All Cases |
All sites |
65-95% |
50-65% |
30-60% |
5-50% |
|
Larynx
Sub Site |
Stage I |
Stage II |
Stage III |
Stage IV |
All Cases |
Supraglottis |
75-85%2 |
55-65%2 |
45-75%3 |
15-35%3 |
|
Glottis |
85-95%2 |
60-80%2 |
55-70%3 |
10-25%3 |
|
Subglottis |
X |
30-40%2 |
X |
X |
|
Salivary glands
Sub Site |
Stage I |
Stage II |
Stage III |
Stage IV |
All Cases |
All sites |
90% |
55% |
45% |
10% |
|
Paranasal sinuses
Sub Site |
Stage I |
Stage II |
Stage III |
Stage IV |
All Cases |
Maxillary sinus |
60-70% |
60-70% |
25-35% |
10-25% |
|
Thyroid gland
Sub Site |
Stage I |
Stage II |
Stage III |
Stage IV |
All Cases |
Papillary carcinoma |
>95% |
>95% |
60% |
X |
|
Follicular carcinoma |
70-90% |
50-70% |
20-60% |
X |
|
Medullary carcinoma |
>95%4 |
50-95%4 |
15-50%4 |
<15%4 |
40-60% |
Anaplastic carcinoma |
|
|
|
|
0-25% |
1 — local control rate (including salvage treatment for some sites)
2 — disease-free
3 — 3-year disease-free
4 — 10 year survival
X — no data available